BioPharma Dive

Don’t miss our in-depth look at what’s ahead for biotech and pharma in 2026. From groundbreaking therapies to regulatory updates, discover the trends that will define the industry. Get the free report: biopharmadive.com/news/biotech-p…

Earendil Labs, an AI-powered drugmaker, hauls in $787M biopharmadive.com/news/earendil-… by @BentheFidler

Novo uses FDA voucher to win speedy approval of higher-dose Wegovy biopharmadive.com/news/novo-high… $NVO by @BentheFidler

Roche stops work on experimental SMA drug biopharmadive.com/news/roche-sma… $RHHBY by @realJacobBell

Rhythm obesity drug wins broader use from FDA biopharmadive.com/news/rhythm-im… $RYTM by @BentheFidler

Pfizer aims for wider use of PARP drug in prostate cancer with new data biopharmadive.com/news/pfizer-ta… $PFE By Kristin Jensen

AstraZeneca to boost cell therapy capabilities with new China investment biopharmadive.com/news/astrazene… $AZN by @BentheFidler

J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections biopharmadive.com/news/jnj-psori… $JNJ by Kristin Jensen

RBC: Revolution, Xenon, Arrowhead among top takeover targets biopharmadive.com/news/biotech-t… by @realJacobBell

Crossbow raises $77M for new cancer immunotherapies biopharmadive.com/news/crossbow-… by @gwendolynawu

Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers biopharmadive.com/news/excalipoi… by @gwendolynawu

Bicycle to lay off 30% of staff, pivot away from Padcev challenger biopharmadive.com/news/bicycle-l… $BCYC @ByJonGardner

Pfizer’s Ibrance successor moves forward with new study data biopharmadive.com/news/pfizer-br… $PFE by Kristin Jensen

Federal court blocks RFK Jr.’s moves to upend US vaccine policy biopharmadive.com/news/rfk-acip-… by @Lilah_Alvarado

News Roundup: Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy biopharmadive.com/news/sarepta-e…

CytomX surges on positive data for ‘masked’ ADC in colorectal cancer biopharmadive.com/news/cytomx-ve… $CTMX by @Lilah_Alvarado

Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial biopharmadive.com/news/structure… $GPCR @ByJonGardner

News Roundup: Evotec, Vistagen lay off staff; Immutep shares collapse on study failure biopharmadive.com/news/evotec-vi…

With FDA go ahead, a China #biotech notches a first in cell therapy testing biopharmadive.com/news/unixell-f… by @realJacobBell

GSK’s RSV vaccine wins broader FDA clearance biopharmadive.com/news/gsk-arexv… $GSK by @Lilah_Alvarado

Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders biopharmadive.com/news/lilly-obe… $LLY @ByJonGardner